OS Therapies (NYSE:OSTX) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital initiated coverage on shares of OS Therapies (NYSE:OSTX) in a report published on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $19.00 price objective on the stock.

OSTX has been the topic of a number of other reports. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a report on Monday. Maxim Group raised their price objective on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, OS Therapies has a consensus rating of “Buy” and an average target price of $18.00.

OS Therapies Trading Up 13.5 %

NYSE OSTX opened at $1.51 on Wednesday. OS Therapies has a 52-week low of $1.33 and a 52-week high of $7.00. The firm’s 50 day moving average price is $1.82 and its 200-day moving average price is $2.71.

Insider Buying and Selling at OS Therapies

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the transaction, the insider now directly owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC raised its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.